Entero Therapeutics (FRA:366) Total Liabilities : €12.21 Mil (As of Mar. 2024)

View and export this data going back to 2018. Start your Free Trial

What is Entero Therapeutics Total Liabilities?

Entero Therapeutics's Total Liabilities for the quarter that ended in Mar. 2024 was €12.21 Mil.

Entero Therapeutics's quarterly Total Liabilities increased from Sep. 2023 (€2.48 Mil) to Dec. 2023 (€3.01 Mil) and increased from Dec. 2023 (€3.01 Mil) to Mar. 2024 (€12.21 Mil).

Entero Therapeutics's annual Total Liabilities declined from Dec. 2021 (€17.36 Mil) to Dec. 2022 (€2.55 Mil) but then increased from Dec. 2022 (€2.55 Mil) to Dec. 2023 (€3.01 Mil).

Entero Therapeutics Total Liabilities Historical Data

The historical data trend for Entero Therapeutics's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Entero Therapeutics Total Liabilities Chart

Entero Therapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Liabilities

Get a 7-Day Free Trial

3.86

12.79

17.36

2.55

3.01

Entero Therapeutics Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Total Liabilities	Get a 7-Day Free Trial															2.64	3.18	2.48	3.01	12.21

Entero Therapeutics Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Entero Therapeutics's Total Liabilities for the fiscal year that ended in Dec. 2023 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	2.873	+	(0.135	+	-2.2204460492503E-16
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	0)
	=	3.01

Total Liabilities	=	Total Assets (A: Dec. 2023 )	-	Total Equity (A: Dec. 2023 )
	=	6.312	-	3.304
	=	3.01

Entero Therapeutics's Total Liabilities for the quarter that ended in Mar. 2024 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	5.679	+	(6.003	+	0.00099999999999978
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0.525	+	0)
	=	12.21

Total Liabilities	=	Total Assets (Q: Mar. 2024 )	-	Total Equity (Q: Mar. 2024 )
	=	83.843	-	71.635
	=	12.21

Entero Therapeutics Total Liabilities Related Terms

Thank you for viewing the detailed overview of Entero Therapeutics's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Entero Therapeutics (FRA:366) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Entero Therapeutics Inc (FRA:366) » Definitions » Total Liabilities

Comparable Companies

Traded in Other Exchanges

ENTO:USA

Address

777 Yamato Road, Suite 502, Boca Raton, FL, USA, 33431

Website

https://www.firstwavebio.com

First Wave BioPharma Inc is a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal diseases. It is advancing a therapeutic development pipeline populated with multiple clinical-stage programs built around its two proprietary technologies-niclosamide, an oral small molecule with anti-viral and anti-inflammatory properties, and the biologic adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients.

Entero Therapeutics (FRA:366) Headlines

No Headlines